HSIC's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 404.15 -- higher than 91.96% of US-listed equities with positive expected earnings growth.
Of note is the ratio of Henry Schein Inc's sales and general administrative expense to its total operating expenses; 85.7% of US stocks have a lower such ratio.
The volatility of Henry Schein Inc's share price is greater than that of just 15.19% US stocks with at least 200 days of trading history.
Stocks with similar financial metrics, market capitalization, and price volatility to Henry Schein Inc are AAP, JLL, MHK, FNF, and TTC.
Henry Schein Inc. is the world's largest provider of health-care products and services to office-based dental, animal health and medical practitioners. The company was founded in 1932 and is based in Melville, New York.
HSIC Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Henry Schein Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Henry Schein Inc ranked in the 28th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Henry Schein Inc ended up being:
The company's compound free cash flow growth rate over the past 5.73 years comes in at -0.01%; that's greater than only 22.88% of US stocks we're applying DCF forecasting to.
HSIC's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 28.59% of tickers in our DCF set.
The weighted average cost of capital for the company is 8. This value is greater than only 22.72% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Henry Schein Inc? See IONS, BIO, PCRX, WAT, and HAPP.
The surgical face shield is a disposable, loose-fitting device, which creates a physical barrier between the nose and mouth of the wearer and potential contaminants in the immediate environment. Surgical face shields are available at different lengths and materials to
DUBLIN--(BUSINESS WIRE)--The "Global Companion Animal Specialty Drugs Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The companion animal specialty drugs market is poised to grow by $ 2.29 billion during 2020-2024 progressing at a CAGR of 5% during the forecast period. The reports on companion animal specialty drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 v
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced today that it has been named to FORTUNE® magazine’s "Change the World" list, an annual ranking of companies that have had a positive social impact through activities that are part of their core business strategy. Henry Schein was recognized for its role in helping to create the Pandemic Supply Chain Network (PSCN), a public-private partnership aimed at saving lives by strengthening the resilience of the global health s
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) today announced that it has entered into an agreement with Zyris, Inc. (formerly, Isolite Systems) to be the exclusive distributor of their complete dental isolation system. The company is offering Zyris’ complete dental isolation system and its full line of mouthpieces to help dental practitioners, dental assistants, and hygienists have greater control and visibility for dental procedures that require patients’ teeth to be isol